Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
~$11B
P/E ratio
~30×
Div yield
None
EPS (TTM)
$0.68
Adj. EBITDA margin
20.5%
Rev. growth (organic)
+3%
Revenue (2024)
$4.4B
Net leverage
4.3×
In plain English
Elanco is the world's #2 pure-play animal-health company — it discovers, makes and sells medicines, vaccines and parasiticides for pets (dogs & cats) and farm animals (cattle, poultry, swine). Spun out of Eli Lilly in 2018-19 and enlarged by the 2020 Bayer Animal Health deal (Seresto, Advantage), it earns ~$4.4B a year split almost evenly between Pet Health and Farm Animal, while working down the debt that deal left behind.
In simple terms
What Elanco Animal Health Inc. really sells
Elanco is the world's #2 pure-play animal-health company — it discovers, makes and sells medicines, vaccines and parasiticides for pets (dogs & cats) and farm animals (cattle, poultry, swine). Spun out of Eli Lilly in 2018-19 and enlarged by the 2020 Bayer Animal Health deal (Seresto, Advantage), it earns ~$4.4B a year split almost evenly between Pet Health and Farm Animal, while working down the debt that deal left behind.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.